danyelza

Danyelza is the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. Below are several iterations for Danyelza’s new branded campaign.